Alyglo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to early ivig adoption in immunodeficiency, plasma fractionation advancements, increased physician awareness, hospital infusion infrastructure growth, chronic immune disorder management.

The growth in the forecast period can be attributed to rising prevalence of immune disorders, improved diagnostic rates, aging population impact, expansion of home infusion alternatives, strengthened plasma supply networks. Major trends in the forecast period include growing demand for ivig therapies, rising diagnosis of primary immunodeficiency, expansion of hospital-based infusion services, focus on plasma-derived therapy safety, increasing long-term immunoglobulin therapy use.

The increasing prevalence of immunodeficiency diseases is expected to drive the growth of the alyglo market in the coming years. Immunodeficiency diseases are conditions in which the immune system is weakened or functions improperly, making individuals more vulnerable to infections. The rise in immunodeficiency diseases is attributed to factors such as growing environmental pollution, genetic predisposition, improved diagnostic capabilities, and the widespread use of immunosuppressive therapies. Alyglo provides intravenous immunoglobulin (IVIG) therapy to strengthen the immune system in individuals with primary humoral immunodeficiency (PI) by replenishing deficient antibodies. This therapy helps lower the frequency and severity of infections, thereby improving patients’ overall quality of life. For instance, in May 2024, according to the Minnesota Department of Health, a US-based state health agency, 324 new HIV diagnoses were reported in 2023, representing a 24% increase compared to 2022. Therefore, the rising prevalence of immunodeficiency diseases is driving the growth of the alyglo market.

Leading companies operating in the alyglo market are concentrating on expanding their treatment portfolios with advanced therapies, including intravenous immunoglobulins (IGIV), to address complex immune deficiencies, improve patient care, and enhance dosing convenience. Intravenous immunoglobulins are antibody-based therapies derived from human plasma and are used to treat a wide range of immune disorders by supplying functional antibodies that help fight infections. For example, in November 2024, GC Biopharma USA Inc., a US-based biopharmaceutical company, launched ALYGLO, a 10% intravenous immunoglobulin therapy developed specifically for adult patients aged 17 years and older with primary humoral immunodeficiency (PI). The therapy utilizes a novel manufacturing process based on cation exchange chromatography (CEX) to remove coagulation factor XIa (FXIa) to undetectable levels, thereby improving patient safety. The product received FDA approval and provides a new therapeutic option while improving patient access through a limited distribution network of national specialty pharmacy providers.

In August 2024, BioCareSD, a US-based specialty distributor focused on orphan, rare, and ultra-rare diseases, partnered with GC Biopharma. This collaboration is intended to deliver ALYGLO (immune globulin intravenous) to patients with primary humoral immunodeficiency (PI) through BioCareSD’s high-touch service model. The partnership supports personalized patient care and improves treatment outcomes for individuals with rare and complex conditions. GC Biopharma is a South Korea-based pharmaceutical company that manufactures alyglo.

Major companies operating in the alyglo market are GC Biopharma Corp.

North America was the largest region in the alyglo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alyglo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alyglo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the alyglo market by increasing costs associated with plasma collection, fractionation equipment, and cold chain transportation. These impacts are more pronounced in hospital pharmacy and specialty infusion settings. North america and europe experience cost sensitivity due to reliance on plasma-derived imports. However, tariffs are driving investments in regional plasma processing capacity. This is improving long-term supply resilience and availability.

The alyglo market research report is one of a series of new reports that provides alyglo market statistics, including alyglo industry global market size, regional shares, competitors with a alyglo market share, detailed alyglo market segments, market trends and opportunities, and any further data you may need to thrive in the alyglo industry. This alyglo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alyglo is an intravenous immune globulin (IVIG) therapy used to treat primary humoral immunodeficiency (PI), a condition characterized by insufficient antibody production in the body. It contains concentrated human immunoglobulin G (IgG) derived from pooled plasma and is administered intravenously to support immune function by supplying essential antibodies.

The primary clinical indications for alyglo include primary humoral immunodeficiency (PI), secondary immunodeficiency, autoimmune disorders, and bone marrow failure syndromes. Primary humoral immunodeficiency (PI) is a disorder in which the body does not produce adequate antibodies, leading to increased vulnerability to infections, and is managed with immune globulin therapies such as Alyglo to help restore immune protection. The therapy is distributed through multiple channels, including hospital pharmacies and specialty pharmacies, and is used across adult, geriatric, and pediatric patient populations.

The alyglo market consists of sales of immune globulin intravenous (IVIG) liquid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.